Lassa Fever Treatment Market Size & Share, by Symptoms (Seizures, Tremor, Coma, Nausea, Vomiting): Treatment (Medication, Supportive Care); Distribution Channel (Hospital Pharmacy, Retails Pharmacy, E-commerce Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 3641
  • Published Date: Dec 01, 2023
  • Report Format: PDF, PPT

Companies Dominating the Lassa Fever Treatment Landscape

    • Pfizer, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Teva Pharmaceutical Industries Ltd.
    • Mylan N.V.
    • Novartis International AG
    • Sanofi S.A.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Abbott Laboratories
    • Inovio Pharmaceuticals Inc
    • Cipla Limited

Browse Key Market Insights with Data Illustration:


In The News

  • INOVIO, a biotechnology company focused on the development and commercialization of DNA medicines for the treatment and prevention of infectious diseases, cancer, and HPV-related diseases, today announced a collaboration with its partner Epidemic Preparedness Innovations Coalition to develop DNA medicines announced that they had signed an agreement to cancel the event. Following initial analysis of data from a study conducted by INOVIO and funded by CEPI, a product candidate for Lassa fever and Middle East respiratory syndrome has been announced.
  • IAVI, a nonprofit scientific research organization, is conducting a Phase I clinical trial, called IAVI C102, using a novel Lassa fever virus vaccine with support from IAVI, in which volunteers from the PREVAIL clinical trial facility at Redemption Hospital in Monrovia, Liberia announced that they are participating in. Candidates from the Coalition for Infectious Disease Prevention Innovations received vaccinations. This study, sponsored by IAVI, is part of an existing partnership with CEPI that began in 2018 and is a global consortium of IAVI and partners to advance the development of IAVI's LASV vaccine candidate through clinical trial support Phases I and II. Provides up to USD 61.7 million to support.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 3641
  • Published Date: Dec 01, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of lassa fever and growing awareness about the disease of oil are some of the major factors anticipated to drive the growth of oil & gas magnetic ranging market.

The market is anticipated to attain a CAGR of ~13% over the forecast period, i.e., 2024-2036.

The major players in the market are of Novartis International AG, Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Abbott Laboratories, Cipla Limited,, and others.

The medication segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in Middle East and Africa is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying